This Federal statute contrasts with the claims of therapeutic benefits of cannabis’ biochemical constituents such as cannabidiol and THC (tetra-hydro-cannabinol) when the sole FDA indication for their use is a rare childhood (Lennox-Gasteau) seizure disorder.

The first major change to federal marijuana laws may be on the horizon now that it has been leaked the Biden administration intends to reschedule marijuana.

U.S. cannabis policy is already confusing, even before Biden Administration recommended rescheduling marijuana. Here's what you need to know.

The U.S. Drug Enforcement Administration is soon poised to reclassify marijuana as a less dangerous drug, placing it in the arena of medical-use substances like Tylenol and ketamine. The decision would open the door to wider use of medical marijuana programs around the country — if states like Texas act on them.

Canopy Growth Corp., Tilray Brands Inc. and Curaleaf Holdings Inc. were among cannabis stocks that were sliding into the red on Wednesday, a day after news of the federal government’s plans to reclassify marijuana.

N.Y., held a press conference with other Democratic lawmakers to introduce the Cannabis Administration and Opportunity Act. The legislation will aim to change the federal government's approach to handling marijuana,

Reclassifying marijuana from a schedule I substance to schedule III would mark a historic shift in federal policy, but the implications are still murky.

The proposal would move marijuana from the “Schedule I” group to the less tightly regulated “Schedule III." So what does that mean, and what are the implications? Technically, nothing yet. The proposal must be reviewed by the White House Office of Management and Budget,